We discovered an orally active carbapenem, L-084, through pharmacokinetic studies on various prodrug esters of (1R,5S,6S)-6-[(R)-1-hydroxyethyl]-1-methyl-2-[1-(1,3-thiazolin-2-yl)azetidin-3-yl]thio-1-carbapen-2-em-3-carboxylic acid (LJC11,036). L-084 showed a strong antimicrobial activity against Gram-positive and Gram-negative bacteria and exhibited the highest intestinal absorption among synthesized prodrugs of LJC11,036.
通过研究(1R,5S,6S)-6-[(R)-1-羟乙基]-1-甲基-2-[1-(1,3-
噻唑啉-2-基)
吖啶-3-基]
硫-1-碳青霉-2-烯-3-
羧酸(LJC11,036)的各种前药酯的药代动力学,我们发现了一种口服有效的碳青霉烯类药物L-084。L-084对革兰氏阳性和革兰氏阴性细菌显示出强大的抗菌活性,并且在合成的LJC11,036前药中具有最高的肠道吸收率。